Melanoma, Malignant Completed Phase 2 Trials for Aldesleukin (DB00041)

Also known as: Malignant Melanoma / [M]Malignant melanoma NOS / Melanoma / Melanoma malignant

IndicationStatusPhase
DBCOND0107071 (Melanoma, Malignant)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00513604Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic MelanomaTreatment
NCT01480323A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2Treatment